PBE Stock Overview
Invesco Exchange-Traded Fund Trust - Invesco Biotechnology & Genome ETF is an exchange traded fund launched and managed by Invesco Capital Management LLC.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Invesco Exchange-Traded Fund Trust - Invesco Biotechnology & Genome ETF Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$61.15 |
| 52 Week High | US$67.76 |
| 52 Week Low | US$52.47 |
| Beta | 0.82 |
| 1 Month Change | -5.75% |
| 3 Month Change | -5.71% |
| 1 Year Change | -1.29% |
| 3 Year Change | -21.40% |
| 5 Year Change | 17.16% |
| Change since IPO | 315.12% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| PBE | US Capital Markets | US Market | |
|---|---|---|---|
| 7D | 0.7% | -0.7% | -3.2% |
| 1Y | -1.3% | 23.2% | 19.3% |
Return vs Industry: PBE underperformed the US Capital Markets industry which returned 23.2% over the past year.
Return vs Market: PBE underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| PBE volatility | |
|---|---|
| PBE Average Weekly Movement | 2.6% |
| Capital Markets Industry Average Movement | 3.4% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PBE has not had significant price volatility in the past 3 months.
Volatility Over Time: PBE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | n/a | www.invesco.com/us/financial-products/etfs/product-detail?productId=ETF-PBE |
Invesco Exchange-Traded Fund Trust - Invesco Biotechnology & Genome ETF is an exchange traded fund launched and managed by Invesco Capital Management LLC. It invests in public equity markets of the United States. The fund invests in stocks of companies operating across biotechnology and genome companies sectors.
Invesco Exchange-Traded Fund Trust - Invesco Biotechnology & Genome ETF Fundamentals Summary
| PBE fundamental statistics | |
|---|---|
| Market cap | US$228.93m |
| Earnings (TTM) | -US$38.56m |
| Revenue (TTM) | US$1.10m |
210.2x
P/S Ratio-6.0x
P/E RatioIs PBE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBE income statement (TTM) | |
|---|---|
| Revenue | US$1.10m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.10m |
| Other Expenses | US$39.66m |
| Earnings | -US$38.56m |
Last Reported Earnings
Oct 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.17 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,496.64% |
| Debt/Equity Ratio | 0% |
How did PBE perform over the long term?
See historical performance and comparison